Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2004-07-30
2009-08-18
Yaen, Christopher H (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Reexamination Certificate
active
07576177
ABSTRACT:
According to the present invention it is now disclosed that exposure of antigen presenting cells, particularly dendritic cells, to peptides or peptide analogs derived from heat shock proteins will subsequently activate T cells to produce immunomodulatory cytokines and will directly influence the cytokines, chemokines, and surface antigens produced by the exposed antigen presenting cells. The present invention relates to peptides and peptide analogs of heat shock proteins capable of interacting directly with dendritic cells. The present invention further relates to pharmaceutical compositions that include dendritic cells exposed to such peptides and analogs, useful for prevention or treatment of either inflammatory disorders and autoimmune diseases or malignancies, viral infections and allergy.
REFERENCES:
patent: 5114844 (1992-05-01), Cohen et al.
patent: 5348945 (1994-09-01), Berberian et al.
patent: 5578303 (1996-11-01), Cohen et al.
patent: 5671848 (1997-09-01), Cohen et al.
patent: 5736146 (1998-04-01), Cohen et al.
patent: 5780034 (1998-07-01), Cohen et al.
patent: 5869058 (1999-02-01), Cohen et al.
patent: 5958416 (1999-09-01), Birnbaum et al.
patent: 5993803 (1999-11-01), Cohen et al.
patent: 6180103 (2001-01-01), Cohen et al.
patent: 6322790 (2001-11-01), Srivastava
patent: 0 262 710 (1992-08-01), None
patent: 9-241159 (1997-09-01), None
patent: 10-212230 (1998-08-01), None
patent: WO 89/12455 (1989-12-01), None
patent: WO 91/02542 (1991-03-01), None
patent: WO 92/04049 (1992-03-01), None
patent: WO 94/02509 (1994-02-01), None
patent: WO 94/03208 (1994-02-01), None
patent: WO 94/29459 (1994-12-01), None
patent: WO 95/25744 (1995-09-01), None
patent: WO 96/10039 (1996-04-01), None
patent: WO 96/16083 (1996-05-01), None
patent: WO 96/18646 (1996-06-01), None
patent: WO 96 19236 (1996-06-01), None
patent: WO 96/19236 (1996-06-01), None
patent: WO 97/01959 (1997-01-01), None
patent: WO 97/11966 (1997-04-01), None
patent: WO 98/08536 (1998-03-01), None
patent: WO 00/27870 (2000-05-01), None
patent: WO 01/04344 (2001-01-01), None
patent: WO 01/43691 (2001-06-01), None
Ngo et al., in The Protein Folding Problem and Tertiary Structure Prediction, 1994, Merz, et al., (ed.), Birkhauser, Boston, MA, pp. 433 and 492-495.
Burgess et al., J of Cell Bio. 111:2129-2138, 1990.
Lazar et al. Molecular and Cellular Biology 8:1247-1252, 1988.
Bowie et al. Science, 247:1306-1310, 1990, p. 1306, col. 2.
Aoki et al (Cancer Immunol Immunother. Nov 2001 ;50(9):463-8).
Zitvogel et al (J Exp Med. Jan. 1, 1996;183(1):87-97).
Springer (Nature Aug. 1990 346:425-435).
Ohad S. Birk, et al., “The 60-kDa Heat Shock Protein Modulates Allograft Rejection”, Proc. Natl. Acad. Sci. USA, vol. 96, pp. 5159-5163 (1999).
Tatsuya Ohkawara, et. al., “Amelioration of Dextran Sulfate Sodium-Induced Colitis by Anti-macrophage Migration Inhibitory Factor Antibody in Mice”, Gastroenterology, vol. 12, pp. 256-270 (2002).
Omathanu Pillai, et al., “Polymers In Drug Delivery”, Current Opinion in Chemical Biology, vol. 5, pp. 447-451 (2001).
Koji Ohashi, et al., “Cutting Edge: Heat Shock Protein 60 Is a Putative Endogenous Ligand of the Toll-Like Receptor-4 Complex”, Journal of Immunology, The American Association of Immunologists, pp. 558-561 (2000).
Michael Mähler, et al., “Genetic Analysis of Susceptibility to Dextran Sulfate Sodium-Induced Colitis in Mice”, Genomics, vol. 55, pp. 147-156 (1999).
Charles A. Janeway, Jr., “How The Immune System Works To Protect The Host From Infection: A Personal View”, PNAS, vol. 98, No. 13, pp. 7461-7468 (2001).
Michael Whelan, et al., “A Filarial Nematode-Secreted Product Signals Dendritic Cells to Acquire a Phenotype that Drives Development of Th2 Cells”, Journal of Immunology, vol. 164, pp. 6453-6460 (2000).
Wei Chen, et al., “Human 60-kDa Heat-Shock Protein: A Danger Signal to the Innate Immune System”, The American Association of Immunologists, Journal of Immunology, vol. 162, pp. 3212-3219 (1999).
Colin C. Anderson, et al., “Danger: The View From The Bottom Of The Cliff”, Seminars in Immunology, vol. 12, pp. 231-238 (2000).
Dana Elias, et al., “Vaccination Against Autoimmune Mouse Diabetes With A T-Cell Epitope Of The Human 65-kDa Heat Shock Protein”, Proc. Natl. Acad. Sci. USA, vol. 88, pp. 3088-3091, Medical Sciences (1991).
Willem van Eden, et al., “Cloning Of The Mycobacterial Epitope Recognized By T Lymphocytes In Adjuvant Arthritis”, Nature, vol. 331, pp. 171-173 (1988).
Willem van Eden, et al., “Do Heat Shock Proteins Control The Balance Of T-Cell Regulation In Inflammatory Diseases?”, Immunology Today, Copyright © 1998 Elsevier Science Ltd., (1998).
Jörg Becker, et al., “Review, Heat-Shock Proteins As Molecular Chaperones”, Eur. J. Biochem., vol. 219, pp. 11-23 (1994).
Suzue et al., “Heat Shock Fusion Proteins As Vehicles For Antigen Delivery Into The Major Histocompatibility Complex Class 1 Presentation Pathway”, Proc. Natl. Academy. Sci., vol. 94, No. 24, pp. 13146-13151 (1997).
P. Srivastava, “Interation Of Heat Shock Proteins With Peptides And Antigen Presenting Cells; Chaperoning Of The Innate And Adaptive Immune Responses”, Annu. Rev. Immunol., vol. 20, pp. 395-425 (2002).
Srivastava et al., “Heat Shock Protein Transfer Peptides During Antigen Processing And CTL Printing”, Immunogenetics, vol. 39, No. 2, pp. 93-98 (1994).
Harpreet Singh-Jasuja et al., “The Heat Shock Protein gp96 Induces Maturation Of Dendritic Cells And Down-Regulation Of Its Receptor”, Eur. J. Immunol, vol. 30, pp. 2211-2215 (2000).
Robert J. Binder et al., “Cutting Edge: Heat Shock Protein gp96 Induces Maturation and Migration of CD11c+Cells In Vivo”, Journal of Immunology, vol. 165, pp. 6029-6035 (2000).
Itamar Raz, et al., “β-Cell Function In New-Onset Type 1: Diabetes And Immunomodulation With A Heat-Shock Protein Peptide (Diapep277): A Randomised, DoubleBlind, Phase II Trial”, The Lancet, vol. 358 No. 9295, pp. 1749-1753 (2001).
Avron Ann
Elias Dana
Karmon Yoram
Andromeda Biotech Ltd.
Winston & Strawn LLP
Yaen Christopher H
LandOfFree
Hsp peptides and analogs for modulation of immune responses... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hsp peptides and analogs for modulation of immune responses..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hsp peptides and analogs for modulation of immune responses... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4103180